Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
Investing.com - Jefferies initiated coverage on Oxford Biomedica (OTC:OXBDF) with a Buy rating and a price target of GBP5.66, according to a research note released Tuesday.
The research firm identified Oxford Biomedica as a "high-quality CGT CDMO" that appears undervalued amid current uncertainties in the sector.
Jefferies noted that despite the company’s "strong track record of excellence, commercial experience, and other key metrics for customers," Oxford Biomedica shares have weakened year-to-date.
The firm’s analysis indicates the current share price reflects below-market and below-guidance growth expectations for 2025-2030.
Jefferies concluded that Oxford Biomedica shares offer "strong upside" potential if the company achieves its targets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.